Works matching DE "SIPULEUCEL-T (Drug)"

Results: 56

Therapeutic metastatic prostate cancer vaccines: lessons learnt from urologic oncology.

Published in:

Central European Journal of Urology (2080-4806), 2021, v. 74, n. 3, p. 300, doi. 10.5173/ceju.2021.0094

By:

Lasek, Witold;
Zapała, Łukasz

Publication type:

Article

Rush Hour Traffic: Directing T Cells to Tumor.

Published in:

2014

By:

Neelapu, Sattva S.;
Kwak, Larry W.

Publication type:

Editorial

Activated Lymphocyte Recruitment Into the Tumor Microenvironment Following Preoperative Sipuleucel-T for Localized Prostate Cancer.

Published in:

JNCI: Journal of the National Cancer Institute, 2014, v. 106, n. 11, p. 1, doi. 10.1093/jnci/dju268

By:

Fong, Lawrence;
Carroll, Peter;
Weinberg, Vivian;
Chan, Stephen;
Lewis, Jera;
Corman, John;
Amling, Christopher L.;
Stephenson, Robert A.;
Simko, Jeffrey;
Sheikh, Nadeem A.;
Sims, Robert B.;
Frohlich, Mark W.;
Small, Eric J.

Publication type:

Article

Managing Metastatic Castration-Resistant Prostate Cancer in the Pre-chemotherapy Setting: A Changing Approach in the Era of New Targeted Agents.

Published in:

Drugs, 2016, v. 76, n. 4, p. 421, doi. 10.1007/s40265-015-0530-7

By:

Zafeiriou, Zafeiris;
Jayaram, Anuradha;
Sharp, Adam;
Bono, Johann

Publication type:

Article

Manufacturing Sipuleucel-T First FDA-approved immunotherapy for men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer.

Published in:

Urology Times, 2013, p. 2

By:

Van Mouwerik, Tim

Publication type:

Article

How Cancers Escape Immune Destruction and Mechanisms of Action for the New Significantly Active Immune Therapies: Helping Nonimmunologists Decipher Recent Advances.

Published in:

Oncologist, 2016, v. 21, n. 2, p. 233, doi. 10.1634/theoncologist.2015-0282

By:

Messerschmidt, Jonathan L.;
Prendergast, George C.;
Messerschmidt, Gerald L.

Publication type:

Article

Perspectives on Treatment of Metastatic Castration-Resistant Prostate Cancer.

Published in:

Oncologist, 2013, v. 18, n. 5, p. 558, doi. 10.1634/theoncologist.2012-0478

By:

Merseburger, Axel S.;
Bellmunt, Joaquim;
Jenkins, Cheryl;
Parker, Chris;
Fitzpatrick, John M.

Publication type:

Article

Real-World Treatment Patterns in Patients with Castrate-Resistant Prostate Cancer and Bone Metastases.

Published in:

American Health & Drug Benefits, 2019, v. 12, n. 3, p. 142

By:

Wen, Lonnie;
Valderrama, Adriana;
Costantino, Mary E.;
Simmons, Stacey

Publication type:

Article

A changing landscape in castration-resistant prostate cancer treatment.

Published in:

Frontiers in Endocrinology, 2012, v. 3, p. 1, doi. 10.3389/fendo.2012.00085

By:

Felici, A.;
Pino, M. S.;
Carlini, Paolo

Publication type:

Article

Molecular insights into the development of T cell-based immunotherapy for prostate cancer.

Published in:

Expert Review of Clinical Immunology, 2014, v. 10, n. 11, p. 1547, doi. 10.1586/1744666X.2014.962515

By:

Dong, Baijun;
Minze, Laurie J;
Xue, Wei;
Chen, Wenhao

Publication type:

Article

Novel agents in the management of castration resistant prostate cancer.

Published in:

Journal of Carcinogenesis, 2014, v. 13, n. 1, p. 1, doi. 10.4103/1477-3163.128185

By:

Chaturvedi, Shruti;
Garcia, Jorge A.

Publication type:

Article

The treatment of metastatic prostate cancer.

Published in:

Nurse Prescribing, 2017, v. 15, n. 4, p. 182, doi. 10.12968/npre.2017.15.4.182

By:

Meade, Elizabeth

Publication type:

Article

Sipuleucel-T: When and for Whom to Recommend It.

Published in:

Oncology (08909091), 2017, v. 31, n. 12, p. 900

By:

Slovin, Susan F.

Publication type:

Article

Small Steps That Lead to a Giant Leap for Prostate Cancer Patients.

Published in:

Oncology (08909091), 2014, v. 28, n. 8, p. 652

By:

CRAWFORD, E. DAVID

Publication type:

Article

Clinical predictors of survival in patients with castration-resistant prostate cancer receiving sipuleucel-T cellular immunotherapy.

Published in:

2017

By:

Bilen, Mehmet;
Hess, Kenneth;
Subudhi, Sumit;
Aparicio, Ana;
Kim, Jeri;
Zurita-Saavedra, Amado;
Araujo, John;
Corn, Paul;
Stover, Jessica;
Lin, Sue-Hwa;
Logothetis, Christopher;
Tu, Shi-Ming;
Bilen, Mehmet Asim;
Hess, Kenneth R;
Subudhi, Sumit K;
Zurita-Saavedra, Amado J;
Araujo, John C;
Corn, Paul G;
Logothetis, Christopher J

Publication type:

journal article

Phase I clinical trial of sipuleucel-T combined with escalating doses of ipilimumab in progressive metastatic castrate-resistant prostate cancer.

Published in:

ImmunoTargets & Therapy, 2017, v. 6, p. 11, doi. 10.2147/ITT.S122497

By:

Scholz, Mark;
Yep, Sabrina;
Chancey, Micah;
Kelly, Colleen;
Ken Chau;
Turner, Jeffrey;
Lam, Richard;
Drake, Charles G.

Publication type:

Article

Therapeutic cancer vaccines and combination immunotherapies involving vaccination.

Published in:

ImmunoTargets & Therapy, 2014, v. 3, p. 135, doi. 10.2147/ITT.S40264

By:

Trang Nguyen;
Urban, Julie;
Kalinski, Pawel

Publication type:

Article

Pharmacotherapeutic Management of Metastatic, Castration-Resistant Prostate Cancer in the Elderly: Focus on Non-Chemotherapy Agents.

Published in:

Drugs & Aging, 2014, v. 31, n. 12, p. 873, doi. 10.1007/s40266-014-0224-y

By:

Graff, Julie;
Beer, Tomasz

Publication type:

Article

Challenges to improved therapeutics for metastatic castrate resistant prostate cancer: from recent successes and failures.

Published in:

Journal of Hematology & Oncology, 2012, v. 5, n. 1, p. 35, doi. 10.1186/1756-8722-5-35

By:

Xuan Huang;
Chau, Cindy H;
Fligg, William D

Publication type:

Article

Immunotherapy for prostate cancer: recent developments and future challenges.

Published in:

Cancer & Metastasis Reviews, 2014, v. 33, n. 2/3, p. 641, doi. 10.1007/s10555-013-9479-8

By:

Schweizer, Michael;
Drake, Charles

Publication type:

Article

The use of the EVITA algorithm for clinical assessment of novel agents used in prostate cancer, metastatic melanoma, and systemic lupus erythematosus.

Published in:

European Journal of Clinical Pharmacology, 2014, v. 70, n. 8, p. 983, doi. 10.1007/s00228-014-1698-6

By:

Szucs, Thomas;
Puri, Daniele;
Blank, Patricia

Publication type:

Article

Focus on: Cancer vaccines.

Published in:: Biologist, 2018, v. 65, n. 4, p. 26
Publication type:: Article

Standing Variations Modeling Captures Inter-Individual Heterogeneity in a Deterministic Model of Prostate Cancer Response to Combination Therapy.

Published in:

Cancers, 2021, v. 13, n. 8, p. 1872, doi. 10.3390/cancers13081872

By:

Jain, Harsh Vardhan;
Sorribes, Inmaculada C.;
Handelman, Samuel K.;
Barnaby, Johnna;
Jackson, Trachette L.;
Robson, Craig N

Publication type:

Article

Exploring Essential Issues for Improving Therapeutic Cancer Vaccine Trial Design.

Published in:

Cancers, 2020, v. 12, n. 10, p. 2908, doi. 10.3390/cancers12102908

By:

Baxevanis, Constantin N.;
Fortis, Sotirios P.;
Ardavanis, Alexandros;
Perez, Sonia A.

Publication type:

Article

Treatment Combinations with DNA Vaccines for the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC).

Published in:

Cancers, 2020, v. 12, n. 10, p. 2831, doi. 10.3390/cancers12102831

By:

Gamat-Huber, Melissa;
Jeon, Donghwan;
Johnson, Laura E.;
Moseman, Jena E.;
Muralidhar, Anusha;
Potluri, Hemanth K.;
Rastogi, Ichwaku;
Wargowski, Ellen;
Zahm, Christopher D.;
McNeel, Douglas G.

Publication type:

Article

Design of Outer Membrane Vesicles as Cancer Vaccines: A New Toolkit for Cancer Therapy.

Published in:

Cancers, 2019, v. 11, n. 9, p. 1314, doi. 10.3390/cancers11091314

By:

Zhang, Yingxuan;
Fang, Zheyan;
Li, Ruizhen;
Huang, Xiaotian;
Liu, Qiong

Publication type:

Article

A Perspective of Immunotherapy for Prostate Cancer.

Published in:

Cancers, 2016, v. 8, n. 7, p. 64, doi. 10.3390/cancers8070064

By:

Silvestri, Ida;
Cattarino, Susanna;
Giantulli, Sabrina;
Nazzari, Cristina;
Collalti, Giulia;
Sciarra, Alessandro

Publication type:

Article

The Lack of Predictors for Rapid Progression in Prostate Cancer Patients Receiving Sipuleucel-T.

Published in:

Cancers, 2013, v. 5, n. 2, p. 511, doi. 10.3390/cancers5020511

By:

Laura Ng;
Heck, Wendy;
Lavsa, Stacey;
Crowther, David;
Atkinson, Brad;
Lianchun Xiao;
Araujo, John

Publication type:

Article

Immunotherapy for Prostate Cancer Enters Its Golden Age.

Published in:

Clinical Medicine Insights: Oncology, 2012, n. 6, p. 263, doi. 10.4137/CMO.S7475

By:

Boikos, Sosipatros A.;
Antonarakis, Emmanuel S.

Publication type:

Article

Immunotherapy for Prostate Cancer.

Published in:

AUANews, 2017, v. 22, n. 1, p. 12

By:

Slovin, Susan F.

Publication type:

Article

Multidisciplinary Care for CRPC.

Published in:

AUANews, 2014, v. 19, n. 9, p. 1

By:

Sartor, A. Oliver

Publication type:

Article

Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy.

Published in:

Cancer Immunology, Immunotherapy, 2015, v. 64, n. 6, p. 655, doi. 10.1007/s00262-015-1707-3

By:

Mulders, Peter;
Santis, Maria;
Powles, Thomas;
Fizazi, Karim

Publication type:

Article

Immunotherapy in Prostate Cancer.

Published in:

Üroonkoloji Bülteni, 2019, v. 18, n. 2, p. 67, doi. 10.4274/uob.galenos.2018.1142

By:

Bolat, Deniz;
Haydaroğlu, Ayfer

Publication type:

Article

Therapy for Castration-Resistant Prostate Cancer: Use Disease State as the Guide.

Published in:: Personalized Medicine in Oncology, 2014, v. 3, n. 3, p. 173
Publication type:: Article

Dendritic cell-based vaccination in cancer: therapeutic implications emerging from murine models.

Published in:

Frontiers in Immunology, 2015, p. 1, doi. 10.3389/fimmu.2015.00243

By:

Keon, Soledad Mac;
Ruiz, María Sol;
Gazzaniga, Silvina;
Wainstok, Rosa

Publication type:

Article

What Nurses and Patients Need to Know About Sipulecucel-T Immunotherapy for Prostate Cancer.

Published in:

ONS Connect, 2015, v. 30, n. 2, p. 40

By:

BECZE, ELISA

Publication type:

Article

Manage Immune-Related Adverse Events Associated With Cancer Immunotherapies.

Published in:

ONS Connect, 2014, v. 29, n. 3, p. 36, doi. 10.1188/14.CJON.311-317

By:

BECZE, ELISA

Publication type:

Article

Adverse Events Associated With the Use of Sipuleucel-T Reported to the US Food and Drug Administration's Adverse Event Reporting System, 2010-2017.

Published in:

JAMA Network Open, 2019, v. 2, n. 8, p. e199249, doi. 10.1001/jamanetworkopen.2019.9249

By:

Dores, Graça M.;
Bryant-Genevier, Marthe;
Perez-Vilar, Silvia

Publication type:

Article

Postmarketing Analysis of Sipuleucel-T—The Importance of Real-World Data.

Published in:

2019

By:

Fan, Alice C.;
Leppert, John T.

Publication type:

Opinion

Factors Associated With Use of Sipuleucel-T to Treat Patients With Advanced Prostate Cancer.

Published in:

JAMA Network Open, 2019, v. 2, n. 4, p. e192589, doi. 10.1001/jamanetworkopen.2019.2589

By:

Caram, Megan E. V.;
Ross, Ryan;
Lin, Paul;
Mukherjee, Bhramar

Publication type:

Article

Mechanism of action and clinical activity of tasquinimod in castrate-resistant prostate cancer.

Published in:

OncoTargets & Therapy, 2014, v. 7, p. 223, doi. 10.2147/OTT.S53524

By:

Gupta, Neha;
Al Ustwani, Omar;
Li Shen;
Pili, Roberto

Publication type:

Article

Time to disease-related pain and first opioid use in patients with metastatic castration-resistant prostate cancer treated with sipuleucel-T.

Published in:

Prostate Cancer & Prostatic Diseases, 2014, v. 17, n. 3, p. 259, doi. 10.1038/pcan.2014.21

By:

Small, E J;
Higano, C S;
Kantoff, P W;
Whitmore, J B;
Frohlich, M W;
Petrylak, D P

Publication type:

Article

Heterologous vaccination targeting prostatic acid phosphatase (PAP) using DNA and Listeria vaccines elicits superior anti-tumor immunity dependent on CD4+ T cells elicited by DNA priming.

Published in:

OncoImmunology, 2018, v. 7, n. 8, p. 1, doi. 10.1080/2162402X.2018.1456603

By:

Johnson, Laura E.;
McNeel, Douglas G.;
Brockstedt, Dirk;
Leong, Meredith;
Lauer, Peter;
Theisen, Erin;
Sauer, John-Demian

Publication type:

Article

Perspectives on sipuleucel-T: Its role in the prostate cancer treatment paradigm.

Published in:

OncoImmunology, 2016, v. 5, n. 4, p. N.PAG, doi. 10.1080/2162402X.2015.1107698

By:

Gulley, James L.;
Mulders, Peter;
Albers, Peter;
Banchereau, Jacques;
Bolla, Michel;
Pantel, Klaus;
Powles, Thomas

Publication type:

Article

Novel Insights on the Current and Emerging Treatment Strategies of CRPC.

Published in:

Journal of Managed Care Medicine, 2018, v. 21, n. 4, p. 33

By:

Paller, Channing J.

Publication type:

Article

Sipuleucel-T boosts survival vs abiraterone or enzalutamide alone: Immunotherapy was also associated with fewer emergency department visits.

Published in:

Urology Times, 2020, v. 48, n. 12, p. 24

By:

Broderick, Jason M.

Publication type:

Article

Multifaceted approach addresses pandemic's threat to prostate cancer care: Maker of sipuleucel-T takes steps to meet patient needs during COVID-19 crisis.

Published in:

Urology Times, 2020, v. 48, n. 6, p. 14

By:

Guttman Krader, Cheryl

Publication type:

Article

2-drug combination improves outcomes in bone-metastatic prostate cancer: Results with sipuleucel-T plus radium-223 show progression-free survival of 9 months.

Published in:

2020

By:

Cote, Brittany

Publication type:

Interview

PRACTICING IN A PROSTATE CANCER "REVOLUTION": Applying Key Insights from the PROCEED Real-World Registry to Clinical Practice.

Published in:

Urology Times, 2020, v. 48, n. 3, p. 48

By:

Hafron, Jason M.

Publication type:

Article

Real-world outcomes reported for sipuleucel-T.

Published in:

Urology Times, 2019, v. 47, n. 10, p. 20

By:

Guttman Krader, Cheryl

Publication type:

Article